First page of the Report "Analysis of 2021 U.S FDA 483 GMP Observations"

Report – Analysis of 2021 U.S FDA 483 GMP Observations

By

Barbara W. Unger

,

Areas examined in this report:

  • The total number of FDA form 483 observations in FY2021
  • Common themes from FDA 483 observations issued in FY2021
  • How these observations compare to previous years’ observations
Logo of AMGEN
Logo of Abbvie
Logo of AstraZeneca
Logo of Baxter
Logo of Genentech
Logo of Lilly
Logo of Merck
Logo of Philips Healthcare
Logo of UCB
Logo of AMGEN
Logo of Abbvie
Logo of AstraZeneca
Logo of Baxter
Logo of Genentech
Logo of Lilly
Logo of Merck
Logo of Philips Healthcare
Logo of UCB
If you have trouble with the form, please contact events@redica.com.

Access the white paper

If you have trouble with the form, please contact events@redica.com.